Avacta Group Plc
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more
Market Cap & Net Worth: Avacta Group Plc (AVCTF)
Avacta Group Plc (PINK:AVCTF) has a market capitalization of $227.57 Million ($227.57 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #15664 globally and #6121 in its home market, demonstrating a 0.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avacta Group Plc's stock price $0.52 by its total outstanding shares 437633189 (437.63 Million).
Avacta Group Plc Market Cap History: 2020 to 2025
Avacta Group Plc's market capitalization history from 2020 to 2025. Data shows change from $634.57 Million to $227.57 Million (-18.84% CAGR).
Avacta Group Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avacta Group Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2526.65x
Avacta Group Plc's market cap is 2526.65 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $634.57 Million | $3.64 Million | -$18.89 Million | 174.52x | N/A |
| 2021 | $678.33 Million | $2.94 Million | -$26.32 Million | 230.65x | N/A |
| 2022 | $691.42 Million | $9.65 Million | -$39.19 Million | 71.63x | N/A |
| 2023 | $708.97 Million | $23.25 Million | -$24.95 Million | 30.50x | N/A |
| 2024 | $285.51 Million | $113.00K | -$52.84 Million | 2526.65x | N/A |
Competitor Companies of AVCTF by Market Capitalization
Companies near Avacta Group Plc in the global market cap rankings as of March 18, 2026.
Key companies related to Avacta Group Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Avacta Group Plc Historical Marketcap From 2020 to 2025
Between 2020 and today, Avacta Group Plc's market cap moved from $634.57 Million to $ 227.57 Million, with a yearly change of -18.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $227.57 Million | -20.29% |
| 2024 | $285.51 Million | -59.73% |
| 2023 | $708.97 Million | +2.54% |
| 2022 | $691.42 Million | +1.93% |
| 2021 | $678.33 Million | +6.90% |
| 2020 | $634.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Avacta Group Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $227.57 Million USD |
| MoneyControl | $227.57 Million USD |
| MarketWatch | $227.57 Million USD |
| marketcap.company | $227.57 Million USD |
| Reuters | $227.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.